Publication | Open Access
Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene‐related peptide responsive receptors
15
Citations
48
References
2023
Year
Despite being designed to target the CGRP receptor, erenumab can antagonise the AMY<sub>1</sub> receptor. Its ability to antagonise CGRP activity at both receptors may be useful in better understanding the clinical profile of erenumab.
| Year | Citations | |
|---|---|---|
Page 1
Page 1